Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NBMX - National Boston Medical (was FGRX) -- Ignore unavailable to you. Want to Upgrade?

To: jhild who wrote (917)	11/13/1998 3:12:00 PM
From: Liberty Capital	Read Replies (6) \| Respond to of 1286

To Jhild and Joe Copia: In response to your questions: 1) Boston Nutriceuticals is a Delaware C Corporation. 2) A statement from the management team from Boston Medical regarding Boston Nutriceuticals will be released in the next few weeks pending final approval of the marketing plan. 3) NBMX releases and signs all the Press Releases verifying the information contained therein. Liberty Capital is only a mouthpiece for NBMX and does not release PRs. We are in conversation with the management team at NBMX to clarify any information causing confusion and answer any questions regarding the company. 4) The following are answers to Jhild's questions in post #917. Re: "Could you provide an exact citation with the FDA for NBMX's announced approval of the Verta line of products?": We are working on finding out about FDA approval; this is a top priority. Re: "Maybe you could craft a better explanation of this passage in that press release . . . 'VERTA VAC is a uniquely newly developed Bio-Formulation consisting of a synergistic blend of selected activity resulting in a breakdown of tissues, oil, blood, and organic matter in dental evacuation systems'": Press Releases prior to Nov. 11, 1998 were made by Fragrance Express, not Boston Medical or Liberty Capital. Re: "Please explain the current corporate structure of NBMX.": It has come to our attention that Baron Marney was not well liked, and is probably not a good source for due diligence. We have been working with NBMX for four days and are doing our own due diligence. We will have all the corporate charts and structure on our website within the next three weeks at libertycap.com. We share Jhild's boundless enthusiasm for having the above questions answered. It's nice to see he is eager to get this information. We are aware that Baron Marney caused some confusion, however, it is obvious to all NBMX investors that Jhild wishes to remain anonymous, which brings into question his status as a shareholder. If you are truly shareholders of the company, why not help build shareholder value instead of tearing it down and bashing the new PR firm? We appreciate the fact that Mr. Copia disclosed his real information on the web (your web page looks good!). All we found in Jhild's profile was the date he started posting and his handle. Liberty Capital disclosed their position with the company, and if Jhild is not interested in posting his information, we must assume that he is a shorter of the stock and that anyone working in consort with Jhild is also a shorter of the stock. Shareholders should remember that anonymous is synonymous with shorter! Siv K. Ostlund Internet Research and Relations Liberty Capital Group, Inc. research@libertycap.com libertycap.com This information is not a solicitation to buy or sell securities. Investors should always consult a registered investment advisor before making any investment decisions. Liberty Capital Group (LCG) picked National Boston ("the Company") due to the tremendous growth potential in the market for antibacterial products. Additionally, LCG feels that the alliances the Company has developed over the last few months will help propel National Boston to a large and sustained revenue stream. Due to the above, LCG has agreed to a contract with National Boston as their financial and public relations firm. LCG's contract is a full one year term and will include fees and cash of between $732,000 - $756,000. Due to huge market potential, LCG has agreed to invest up to $500,000 through an option, with prices scaled from $1.00/sh - $7.00/sh.

To: jhild who wrote (917)	11/17/1998 3:09:00 PM
From: Liberty Capital	Read Replies (3) \| Respond to of 1286

To Jhild: In response to your question regarding the "citation with the FDA for NBMX's announced approval of the Verta Line of products," there is an approval number, #973765 510k under the name Bio2000. It has exactly the same product manufacturer as Verta Line, just a different name. Verta Line does not have to clear FDA approval again, we only have to receive a new number. Verta Vac was acquired from Micrilium Laboratories with FDA approval. To answer your question regarding the following passage: "VERTAVAC is a uniquely newly developed Bio-Formulation consisting of a synergistic blend of selected activity resulting in a breakdown of tissues, oil, blood, and organic matter in dental evacuation systems." Verta Vac is an enzymatic and bacterial cleaning solution that is used to clean the dental vacuum systems. It is flushed through the vacuum system, promoting the breakdown of plaque on the vacuum system walls, but does not leave a residue. Verta Vac uses no chemicals and is bio-degradable. Verta Line and Verta Son do not require FDA approval. All Bontempi instruments are categorized and numbered according to FDA standards; there is no FDA approval necessary. Be sure to visit our web site at libertycap.com in the next few weeks, as we will be posting new information on NBMX within the next three weeks that should hopefully answer any other questions you might have. Please feel free to call Tom Raack at Liberty Capital with your questions, 360.676.8072. Liberty Capital Group, Inc. research@libertycap.com libertycap.com This information is not a solicitation to buy or sell securities. Investors should always consult a registered investment advisor before making any investment decisions. Liberty Capital Group (LCG) picked National Boston ("the Company") due to the tremendous growth potential in the market for antibacterial products. Additionally, LCG feels that the alliances the Company has developed over the last few months will help propel National Boston to a large and sustained revenue stream. Due to the above, LCG has agreed to a contract with National Boston as their financial and public relations firm. LCG's contract is a full one year term and will include fees and cash of between $732,000 - $756,000. Due to huge market potential, LCG has agreed to invest up to $500,000 through an option, with prices scaled from $1.00/sh - $7.00/sh.